What the FDA labels say about taking them together
Glecaprevir/pibrentasvir and rifampin
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names rifampin in its contraindications section; the rifampin label PlainMeds reads does not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “Coadministration is contraindicated because of potential loss of therapeutic effect.”
Check it at the source: the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the glecaprevir/pibrentasvir label say about rifampin?
Glecaprevir/pibrentasvir label, contraindicationsMAVYRET is contraindicated with atazanavir or rifampin [see Drug Interaction ( 7.3 ) and Clinical Pharmacology ( 12.3 )].
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Rifampin; Effect on Concentration: ↓ glecaprevir ↓ pibrentasvir; Clinical Comments: Coadministration is contraindicated because of potential loss of therapeutic effect [see Contraindications () ].
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What does the rifampin label say about glecaprevir/pibrentasvir?
Rifampin's label (effective February 11, 2026) does not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glecaprevir/pibrentasvir | Rifampin | |
|---|---|---|
| Labeled for | Hepatitis C | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.98 per tablet 100-40 mg tablet | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once